JP4498480B2 - Nasal formulation - Google Patents
Nasal formulation Download PDFInfo
- Publication number
- JP4498480B2 JP4498480B2 JP36219197A JP36219197A JP4498480B2 JP 4498480 B2 JP4498480 B2 JP 4498480B2 JP 36219197 A JP36219197 A JP 36219197A JP 36219197 A JP36219197 A JP 36219197A JP 4498480 B2 JP4498480 B2 JP 4498480B2
- Authority
- JP
- Japan
- Prior art keywords
- resin
- spray
- fluororesin
- wall surface
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【０００１】
【発明の属する技術分野】
本発明は特定の容器に充填された点鼻用製剤に関する。
【０００２】
【従来の技術】
鼻みず、鼻づまり等の鼻炎症状の緩解のために、従来抗ヒスタミン剤、殺菌剤、血管収縮剤などに加えて、メントール等のテルペノイドを清涼剤として配合した点鼻液が用いられ、それはポリエチレン又はポリプロピレン製の手動加圧式スプレー容器に充填して市販されている。
【０００３】
【発明が解決しようとする課題】
本発明者らの研究の結果、テルペノイドを配合した点鼻薬をポリエチレンやポリプロピレン製のスプレー容器に充填するとテルペノイドが保存中に容器材料に吸収浸透、揮散してその含有量を長期間保持できないことが判った。
本発明はスプレー容器に充填したテルペノイド含有点鼻用製剤からテルペノイドの吸収浸透及び揮散を抑制して長期間の保存を可能にしようとするものである。
【０００４】
【課題を解決するための手段】
本発明は、テルペノイド含有点鼻剤を、薬剤充填時に薬剤に接する内壁面の材料がエポキシ樹脂、ポリアミドイミド樹脂又はフッ素樹脂であるスプレー容器に充填してなる点鼻用製剤である。
【０００５】
【実施の態様】
テルペノイドにはモノテルペン、セスキテルペン、ジテルペンが包含され、その例としては、メントール、ボルネオール、カンフル、ゲラニオール、シネオール、アネトール、リモネン、オイゲノール、ユーカリ油、ファルネソール、ネロリドール、フィトール又はセンブレンなどが挙げられる。好ましいのはメントール、ボルネオール、カンフル、ユーカリ油などである。
【０００６】
テルペノイドは点鼻剤中に、必要に応じて選択される他の成分、例えば血管収縮剤、抗ヒスタミン剤、殺菌剤、消炎剤、局所麻酔剤、抗アレルギー剤、収斂剤などと共に配合することができる。
【０００７】
本発明において、スプレー容器の充填薬剤に接する内壁面を形成する材料であるエポキシ樹脂としては、例えばエポキシフェノール樹脂が挙げられ、フッ素樹脂としては、例えばフッ化ビニリデン樹脂が挙げられる。
スプレー容器における充填薬剤に接する内壁面をこれらの樹脂で形成するには薬剤充填部自体をこれらの樹脂で作製してもよく、またこれらの樹脂で内壁面を塗装して樹脂の被膜として形成させてもよい。これらの樹脂面は充填された点鼻剤中のテルペノイドの吸収、揮散を妨げ、その含有量低下を抑制することができる。
【０００８】
スプレー容器は手動噴射式又は自動噴射式スプレー容器を包含する。自動噴射式の場合はフロンやＬＰＧのような液化ガスの代りに圧縮空気などの圧縮ガスを用いることもできる。
【０００９】
【実施例】
以下に実施例の形で本発明をさらに説明する。
【００１０】
実施例
試験液（点鼻薬）
〔処方〕
〔試験方法〕
ポリエチレン製及びポリプロピレン製の各容器（容量 5.5ml）にそれぞれ試験液 5mlを入れて気密にし、また、内壁面に内面コート剤のエポキシフェノール、ポリアミドイミド又はフッ化ビニリデン樹脂を塗布した各アルミ缶容器（容量１５ml）にそれぞれ試験液１４mlと圧縮空気（６．５Ｋｇ／ｃｍ2 ）を入れて気密にし、室温で静置、保存した。４週間経過後、各試験液中のｌ−メントール及びユーカリ油の残存量をガスクロマトグラフィーにより測定した。
結果は下表のとおりである。
【００１２】
〔試験結果〕
残存率（単位：％）
表から明かなように、ポリエチレン製の容器では、ｌ−メントール及びユーカリ油が残存せず、ポリプロピレン製容器では残存率がそれぞれ僅かに１５．６％及び１６．５％である。一方、エポキシフェノール、ポリアミドイミド又はフッ化ビニリデン樹脂を内壁面に塗布した容器では残存率がそれぞれ６５．２〜６７．１％及び７６．３〜７８．９％を示した。この結果からエポキシフェノール、ポリアミドイミド、及びフッ化ビニリデン樹脂で内壁面が形成された容器には充填された薬剤中のテルペノイドの減少を顕著に抑制することが判る。
【００１４】
【発明の効果】
本発明によれば、スプレー容器に充填されたテルペノイド含有点鼻剤中のテルペノイドが保存中に減少するのを抑制することができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a nasal preparation filled in a specific container.
[0002]
[Prior art]
In order to relieve nasal inflammation such as nasal congestion and nasal congestion, nasal drops containing terpenoids such as menthol as a refreshing agent in addition to antihistamines, bactericides, vasoconstrictors, etc. are used. Commercially available manually pressurized spray containers filled.
[0003]
[Problems to be solved by the invention]
As a result of our research, when nasal drops containing terpenoids are filled in a spray container made of polyethylene or polypropylene, the terpenoids cannot absorb and permeate into the container material during storage and keep its content for a long time. understood.
The present invention is intended to enable long-term storage by suppressing absorption penetration and volatilization of terpenoids from a terpenoid-containing nasal preparation filled in a spray container.
[0004]
[Means for Solving the Problems]
The present invention is a nasal preparation prepared by filling a terpenoid-containing nasal drop into a spray container in which the material of the inner wall surface that comes into contact with the drug at the time of drug filling is an epoxy resin, a polyamideimide resin, or a fluororesin.
[0005]
Embodiment
Terpenoids include monoterpenes, sesquiterpenes, diterpenes, examples of which include menthol, borneol, camphor, geraniol, cineol, anethole, limonene, eugenol, eucalyptus oil, farnesol, nerolidol, phytol or semblene. . Preference is given to menthol, borneol, camphor, eucalyptus oil and the like.
[0006]
Terpenoids can be blended in nasal drops with other components selected as necessary, for example, vasoconstrictors, antihistamines, bactericides, anti-inflammatory agents, local anesthetics, antiallergic agents, astringents and the like.
[0007]
In the present invention, examples of the epoxy resin that is a material forming the inner wall surface in contact with the filling agent of the spray container include an epoxy phenol resin, and examples of the fluororesin include a vinylidene fluoride resin.
In order to form the inner wall surface in contact with the filling drug in the spray container with these resins, the drug filling part itself may be made of these resins, or the inner wall surface may be painted with these resins to form a resin film. May be. These resin surfaces prevent absorption and volatilization of terpenoids in the filled nasal drops, and can suppress a decrease in the content thereof.
[0008]
Spray containers include manual spray or automatic spray spray containers. In the case of the automatic injection type, a compressed gas such as compressed air can be used instead of a liquefied gas such as Freon or LPG.
[0009]
【Example】
The invention is further described below in the form of examples.
[0010]
Example test solution (nasal drops)
[Prescription]
〔Test method〕
Each aluminum can container in which 5 ml of the test solution is put in a polyethylene container and a polypropylene container (capacity 5.5 ml), respectively, and the inner wall surface is coated with epoxyphenol, polyamideimide, or vinylidene fluoride resin. The test solution (14 ml) and compressed air (6.5 Kg / cm 2 ) were put in each (volume 15 ml) to make it airtight, and allowed to stand and stored at room temperature. After 4 weeks, the residual amounts of l-menthol and eucalyptus oil in each test solution were measured by gas chromatography.
The results are shown in the table below.
[0012]
〔Test results〕
Residual rate (unit:%)
As is apparent from the table, in the polyethylene container, 1-menthol and eucalyptus oil do not remain, and in the polypropylene container, the residual ratios are only 15.6% and 16.5%, respectively. On the other hand, in the container in which epoxyphenol, polyamideimide or vinylidene fluoride resin was applied to the inner wall surface, the residual ratios were 65.2 to 67.1% and 76.3 to 78.9%, respectively. From this result, it can be seen that the reduction of terpenoids in the drug filled in the container having the inner wall surface formed of epoxyphenol, polyamideimide, and vinylidene fluoride resin is remarkably suppressed.
[0014]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, it can suppress that the terpenoid in the terpenoid containing nasal drop filled with the spray container reduces during a preservation | save.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36219197A JP4498480B2 (en) | 1997-12-10 | 1997-12-10 | Nasal formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36219197A JP4498480B2 (en) | 1997-12-10 | 1997-12-10 | Nasal formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007189146A Division JP2007262100A (en) | 2007-07-20 | 2007-07-20 | Method for preventing reduction in content of terpenoid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11171762A JPH11171762A (en) | 1999-06-29 |
| JP4498480B2 true JP4498480B2 (en) | 2010-07-07 |
Family
ID=18476218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP36219197A Expired - Lifetime JP4498480B2 (en) | 1997-12-10 | 1997-12-10 | Nasal formulation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4498480B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001354549A (en) * | 2000-06-08 | 2001-12-25 | Koike Kagaku Kk | Aerosol product for washing nasal cavity |
| TW523409B (en) * | 2000-09-15 | 2003-03-11 | Baxter Int | Container for inhalation anesthetic |
-
1997
- 1997-12-10 JP JP36219197A patent/JP4498480B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11171762A (en) | 1999-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5370862A (en) | Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina | |
| CA2111002C (en) | Non-chlorofluorocarbon aerosol formulations | |
| US4243548A (en) | Pressurized aerosol formulation and process for the manufacture thereof | |
| US5620631A (en) | Pressurized-gas pack and propellant for aerosols | |
| CA2352484C (en) | Pressurised metered dose inhalers (mdi) | |
| US2868691A (en) | Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine | |
| HU208398B (en) | Process for producing pharmaceutical aerosol composition | |
| HUT67445A (en) | Aerosol formulations containing 1,1,1,2-tetrafluorethane | |
| AU721920B2 (en) | Aerosol formulations | |
| EP0499344A2 (en) | Medicinal aerosol formulations | |
| IE83747B1 (en) | Non-chlorofluorocarbon aerosol formulations | |
| CN1331581A (en) | Pharmaceutical aerosol compsn. contg. HFA227 and HFA 137 | |
| JP4498480B2 (en) | Nasal formulation | |
| JP2024019573A (en) | Fluticasone and vilanterol formulations and inhalers | |
| US5618515A (en) | Aerosol spray composition for the treatment of dermal burns by cooling and anesthetizing the wound and valved container for dispensing same | |
| US3974945A (en) | Aerosol dispensing system | |
| US20210237107A1 (en) | Bag on valve technology | |
| EP1811981B1 (en) | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister | |
| JPH04305502A (en) | Foaming aerosol insecticide and application method using | |
| WO1994001511A1 (en) | Pressurised aerosol formulation | |
| JP2642738B2 (en) | Aerosol products for human body application | |
| JP2992762B2 (en) | New composition | |
| JP2007262100A (en) | Method for preventing reduction in content of terpenoid | |
| JP4437649B2 (en) | Microemulsion composition and aerosol agent using the same | |
| JP4578835B2 (en) | Stabilized microemulsion aerosol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050517 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050715 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060516 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060714 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070522 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070720 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100222 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100222 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100414 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140423 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |